Kristen Starbuck
- Department of Gynecology & Obstetrics
Assistant Professor
- (404) 778-3401
- kristen.d.starbuck@emory.edu
Overview
Kristen D. Starbuck, MD, is an Assistant Professor in the Division of Gynecologic Oncology of the Department of Gynecology and Obstetrics at Emory University School of Medicine. As a gynecologic cancer specialist, Dr. Starbuck collaborates with gynecologic cancer teams to deliver top care to patients at Emory Decatur Hospital. She specializes in the treatment of cervical, ovarian, uterine, vulvar and vaginal cancer.
Education
Degrees
- MD from University of Connecticut School of Medicine
Research
Publications
-
Case report: intravenous leiomyomatosis with intracaval and intracardiac growth.
Eur Heart J Case Rep Volume: 7 Page(s): ytac464
01/01/2023 Authors: Kikuchi DS; Goulbourne CA; Starbuck KD; Fernandes MF -
Incidence and predictors of toxicity in the management of vulvar squamous cell carcinoma treated with radiation therapy.
Gynecol Oncol Rep Volume: 44 Page(s): 101086
12/01/2022 Authors: McCall NS; Eng TY; Shelton JW; Hanasoge S; Patel PR; Patel AB; McCook-Veal AA; Switchenko JM; Cole TE; Khanna N -
Recurrent uterine inflammatory myofibroblastic tumor previously managed as leiomyosarcoma has sustained response to alectinib.
Gynecol Oncol Rep Volume: 43 Page(s): 101062
10/01/2022 Authors: Carballo EV; Pham TV; Turashvili G; Hanley K; Starbuck KD; Meisel JL -
Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium.
Cancer Causes Control Volume: 30 Page(s): 537 - 547
05/01/2019 Authors: Minlikeeva AN; Cannioto R; Jensen A; Kjaer SK; Jordan SJ; Diergaarde B; Szender JB; Odunsi K; Almohanna H; Mayor P -
Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau.
Oncotarget Volume: 9 Page(s): 23289 - 23305
05/01/2018 Authors: Starbuck K; Al-Alem L; Eavarone DA; Hernandez SF; Bellio C; Prendergast JM; Stein J; Dransfield DT; Zarrella B; Growdon WB -
Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer.
PLoS One Volume: 13 Page(s): e0206913
01/01/2018 Authors: Starbuck KD; Szender JB; Duncan WD; Morrell K; Etter JL; Zsiros E; Odunsi K; Moysich K; Eng KH -
History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report.
Br J Cancer Volume: 117 Page(s): 1063 - 1069
09/26/2017 Authors: Minlikeeva AN; Freudenheim JL; Cannioto RA; Eng KH; Szender JB; Mayor P; Etter JL; Cramer DW; Diergaarde B; Doherty JA -
Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
Anticancer Res Volume: 36 Page(s): 6161 - 6164
11/01/2016 Authors: Starbuck KD; Drake RD; Budd GT; Rose PG -
Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: a National Cancer Database analysis.
Gynecol Oncol Volume: 139 Page(s): 84 - 89
10/01/2015 Authors: Rauh-Hain JA; Starbuck KD; Meyer LA; Clemmer J; Schorge JO; Lu KH; Del Carmen MG -
Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomas.
Acta Neuropathol Volume: 121 Page(s): 529 - 543
04/01/2011 Authors: Mohapatra G; Engler DA; Starbuck KD; Kim JC; Bernay DC; Scangas GA; Rousseau A; Batchelor TT; Betensky RA; Louis DN